Compare ACRS & LWLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | LWLG |
|---|---|---|
| Founded | 2012 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Containers/Packaging |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.5M | 995.4M |
| IPO Year | 2015 | 2011 |
| Metric | ACRS | LWLG |
|---|---|---|
| Price | $6.28 | $6.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $10.20 | N/A |
| AVG Volume (30 Days) | 1.9M | ★ 3.1M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | 15.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,683,000.00 | $236,855.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 147.74 |
| 52 Week Low | $1.74 | $2.15 |
| 52 Week High | $6.52 | $18.71 |
| Indicator | ACRS | LWLG |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | 40.12 |
| Support Level | $4.13 | $5.61 |
| Resistance Level | $6.52 | $7.92 |
| Average True Range (ATR) | 0.36 | 0.63 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 83.72 | 7.53 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Lightwave Logic Inc is a specialty materials and intellectual property company focused on the development and commercialization of proprietary electro-optic (EO) polymer materials designed to enable high-speed optical modulators for data communications and other photonic applications. Its Perkinamine family of EO polymers is designed for integration into silicon photonics (SiPh) and other photonic integrated circuit (PIC) platforms, supporting high-speed optical modulation with lower drive voltage requirements compared with some conventional silicon-based and III-V compound semiconductor approaches. The company operates as a single reportable segment.